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With considerable interest we read the article by Erbay et al.,
in which the authors examined the risk factors for recurrent
catheter-related bloodstream infections (CR-BSI).1 Although
Erbay et al. also included general ward patients in their
analyses, they found an astonishingly high rate of patients
with recurrent CR-BSI.1 In our opinion this enormous inci-
dence, namely one-third of patients, can firstly be explained
by their definitions; they define recurrent CR-BSI as positive
blood cultures, coupled with positive catheter tip culture ‘or’
no other new source of infection evident. Secondly, it is
conceivable that patients admitted to the intensive care
unit are more prone to non-infectious signs of systemic
inflammation compared to those admitted elsewhere in
the hospital. However, we would have liked the authors to
detail the indications for which blood sampling for culturing
was obtained.
CR-BSI should be treated with systemic antimicrobials for
10—14 days.2 In the article by Erbay et al., no data are given
concerning the time period in which antimicrobials were
administered. Consequently, it may be assumed that some
of the CR-BSIs, now categorized as ‘recurrent CR-BSI’, were
still related to the first episode. Further, it was mentioned
that all patients were given antibiotics; however, no infor-
mation was provided concerning the time delay to the start ofadequate antimicrobials. As appropriateness of empiric anti-
microbial therapy within the first hours following onset of
infection is of key importance to the improvement of patient
outcome, we would be interested in an elaboration of this
issue.3—5
CR-BSIs place a significant burden on healthcare resources
due to the necessity for additional therapies. The increased
morbidity accounts for a significant increase in healthcare
expenditure.6 We congratulate Dr Erbay and colleagues for
their important work at aiming to identify risk factors related
to the development of recurrent CR-BSIs. However, the most
important risk factor for CR-BSI is transmission by means of
the personnel taking care of the patient. Therefore, in
addition to their research, we would like to draw attention
to the fact that the cornerstone of CR-BSI prevention is
education, with performance feedback and on-the-floor pro-
cess control following on.7 As CR-BSIs are largely preventable
nosocomial infections, an intensified teaching program may
heighten awareness among healthcare professionals, so that
standards will become routine.8 It has been proven that this is
one of the most effective, easiest, and least expensive
strategies to reduce CR-BSI rates.9,10 Ultimately, taking full
advantage of knowledge of associated risk factors of CR-BSIs,
in combination with fitting strategies such as education
programs, will lead to reduced antibiotic use and thus alle-
viation of selection pressure.
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doi:10.1016/j.ijid.2006.08.005Thiazolidinediones could be an effective treat-
ment for HIV-associated progressive multifocal
leukoencephalopathy
HIV-associated progressive multi-focal leukoencephalopathy
(PML) is a severe neurodegenerative disorder that leads to
disability and death from fulminant damage to cerebral
white matter. PML is caused by human polyoma JC virus,
an almost ubiquitous virus normally kept in check by the
immune system.1 PML had been common prior to the advent
of highly active anti-retroviral therapy (HAART), and now
some cases are being seen in the context of HAART failure2
and also immune reconstitution syndrome, where a patient’s
HAART-restored immune system attacks brain tissue.3 Cur-
rently available treatments such as interferon are often
ineffective4 and new approaches are needed. I propose
the hypothesis that thiazolidinediones (TZs) such as piogli-
tazone and rosiglitazone, currently used for treatment of
type II diabetes, could potentially slow the course of PML and
under the best of circumstances, induce a complete remis-
sion.
Both basic science and clinical data lend support to the
above idea. TZs have pleiotropic neuroprotective effects
that can be demonstrated in several different animalmodels
of neurodegeneration.5 Neuroprotective effects are
believed to be through anti-inflammatory mechanisms
mediated by the peroxisome-activated gamma receptor.5
TZ stimulation of the peroxisome-activated gamma receptor
suppresses a multitude of inflammatory cytokines both in
cultured cells and in vivo in animal models.5—7 Furthermore,
pioglitazone has been shown to reduce activation of Tlymphocytes from patients with multiple sclerosis,8 and
there is a published case report from 2004 of a 44-year-
old woman with severe progressive multiple sclerosis, com-
plicated by quadriparesis, ataxia, fatigue and cognitive
decline, who had a significant clinical remission taking
pioglitazone.5 Large scale clinical trials with multiple
sclerosis patients are undoubtedly underway now. Given
that multiple sclerosis and PML are both demyelinating
inflammation of the cerebral white matter, it would be
logical to similarly initiate clinical trials in patients with
HIV-associated PML. The trials could be either large rando-
mized placebo controlled studies or ‘n of 1’ longitudinal
studies like that for the patient with multiple sclerosis. TZs
already show promise as a treatment for HAART-associated
lipodystrophy9,10 so from an ethical standpoint potential
benefits to patients would certainly justify open-label ‘n
of 1’ studies, if they are done by HIV specialists who
would insure no deleterious drug interactions with HAART
medications.
In conclusion, potential benefits of TZs for HIV-associated
PML warrant further investigation.
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